東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Development of Meloxicam Containing ...

Party, Petra,

Linked to FindBook

Google Book

Amazon

博客來

Development of Meloxicam Containing Carrier-Free "Nano-In-Micro" Dry Powder Inhaler Systems /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Development of Meloxicam Containing Carrier-Free "Nano-In-Micro" Dry Powder Inhaler Systems // Petra Party.
Author:	Party, Petra,
Description:	1 electronic resource (117 pages)
Notes:	Source: Dissertations Abstracts International, Volume: 86-05, Section: B.
Contained By:	Dissertations Abstracts International86-05B.
Subject:	Cystic fibrosis. -
Online resource:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31744499
ISBN:	9798346588375

Development of Meloxicam Containing Carrier-Free "Nano-In-Micro" Dry Powder Inhaler Systems /
Party, Petra,

Development of Meloxicam Containing Carrier-Free "Nano-In-Micro" Dry Powder Inhaler Systems /Petra Party. - 1 electronic resource (117 pages)

Source: Dissertations Abstracts International, Volume: 86-05, Section: B.

The burden of chronic lung diseases has increased dramatically over the past decades. In terms of prevalence, the five most prominent lung diseases are asthma, tuberculosis, chronic obstructive pulmonary disease (COPD), lung cancer and pneumonia caused by various infections. Local treatment of the conditions compared to oral or parenteral drug delivery could be more efficient with better patient compliance.Among the pulmonary drug delivery systems, the application of dry powder inhalers (DPIs) continues to grow in therapy due to their outstanding stability, ease of use and low production costs. Advantages compared to propellant aerosols are that the inhaled air stream delivers the drug to the airways, which can significantly reduce greenhouse gas emissions. Compared to conventional carrier-based DPIs, carrier-free DPIs are more effective, because the active pharmaceutical ingredient (API) creates a complex system with additives. Due to their special morphology, structure, and better aerodynamic properties, even low respiratory function is enough for proper lung deposition.The majority of APIs used today are poorly water-soluble. Nanosized drugs can provide higher bioavailability due to their smaller particle size and larger specific surface. The various size reduction methods include bottom-up and top-down approaches. Watersolubility can be improved by applying particle engineering techniques that also enable new, alternative administration routes.Although pulmonary therapy would benefit from the use of nanoparticles, there is no commercially available formulation yet. The main challenge is that the required aerodynamic particle size should be between 1-5 µm. For this, the "nano-in-micro" structure could be a solution, having the advantages of nanosized drugs while providing adequate aerodynamic properties. The combination of wet milling, as a top-down particle size reduction method, and spray drying, as a bottom-up technology, could be suitable for their preparation. These systems deposit deeper into the respiratory tract compared to the conventional formulations, while overcoming its elimination mechanisms.It is difficult in pharmaceutical technology to find organic solvent-free, scalable, cost-effective and time-saving techniques that are suitable for the preparation of the "nanoin-micro" DPIs. This thesis reports the development of DPIs containing the non-steroidal anti-inflammatory agent (NSAID) meloxicam (MX) using a combined preparation technique with the aim of effective pulmonary delivery.

English

ISBN: 9798346588375Subjects--Topical Terms:

820635
Cystic fibrosis.

Development of Meloxicam Containing Carrier-Free "Nano-In-Micro" Dry Powder Inhaler Systems /
LDR:03836nmm a22003973i 4500 001 2436529
005 20251023121235.5
006 m o d
007 cr|nu||||||||
008 261011s2024 miu||||||m |||||||eng d
020 $a 9798346588375
035 $a (MiAaPQD)AAI31744499
035 $a (MiAaPQD)Szegeduszegedhu12109
035 $a AAI31744499
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Party, Petra, $e author. $3 3827218
245 1 0 $a Development of Meloxicam Containing Carrier-Free "Nano-In-Micro" Dry Powder Inhaler Systems / $c Petra Party.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (117 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-05, Section: B.
500 $a Advisors: Ambrus, Rita.
502 $b Ph.D. $c University of Szeged (Hungary) $d 2024.
520 $a The burden of chronic lung diseases has increased dramatically over the past decades. In terms of prevalence, the five most prominent lung diseases are asthma, tuberculosis, chronic obstructive pulmonary disease (COPD), lung cancer and pneumonia caused by various infections. Local treatment of the conditions compared to oral or parenteral drug delivery could be more efficient with better patient compliance.Among the pulmonary drug delivery systems, the application of dry powder inhalers (DPIs) continues to grow in therapy due to their outstanding stability, ease of use and low production costs. Advantages compared to propellant aerosols are that the inhaled air stream delivers the drug to the airways, which can significantly reduce greenhouse gas emissions. Compared to conventional carrier-based DPIs, carrier-free DPIs are more effective, because the active pharmaceutical ingredient (API) creates a complex system with additives. Due to their special morphology, structure, and better aerodynamic properties, even low respiratory function is enough for proper lung deposition.The majority of APIs used today are poorly water-soluble. Nanosized drugs can provide higher bioavailability due to their smaller particle size and larger specific surface. The various size reduction methods include bottom-up and top-down approaches. Watersolubility can be improved by applying particle engineering techniques that also enable new, alternative administration routes.Although pulmonary therapy would benefit from the use of nanoparticles, there is no commercially available formulation yet. The main challenge is that the required aerodynamic particle size should be between 1-5 µm. For this, the "nano-in-micro" structure could be a solution, having the advantages of nanosized drugs while providing adequate aerodynamic properties. The combination of wet milling, as a top-down particle size reduction method, and spray drying, as a bottom-up technology, could be suitable for their preparation. These systems deposit deeper into the respiratory tract compared to the conventional formulations, while overcoming its elimination mechanisms.It is difficult in pharmaceutical technology to find organic solvent-free, scalable, cost-effective and time-saving techniques that are suitable for the preparation of the "nanoin-micro" DPIs. This thesis reports the development of DPIs containing the non-steroidal anti-inflammatory agent (NSAID) meloxicam (MX) using a combined preparation technique with the aim of effective pulmonary delivery.
546 $a English
590 $a School code: 1494
650 4 $a Cystic fibrosis. $3 820635
650 4 $a Lung diseases. $3 3704704
650 4 $a Drug delivery systems. $3 657987
650 4 $a Greenhouse gases. $3 797971
650 4 $a Lipids. $3 558980
650 4 $a Coronaviruses. $3 894828
650 4 $a Chronic obstructive pulmonary disease. $3 3558078
650 4 $a COVID-19. $3 3554449
650 4 $a Climate change. $2 bicssc $3 2079509
650 4 $a Medicine. $3 641104
650 4 $a Pharmacology. $3 634543
650 4 $a Virology. $3 642304
690 $a 0404
690 $a 0564
690 $a 0419
690 $a 0720
710 2 $a University of Szeged (Hungary). $e degree granting institution. $3 3759136
720 1 $a Ambrus, Rita $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-05B.
790 $a 1494
791 $a Ph.D.
792 $a 2024
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31744499